Global Blood Therapeutics (GBT) Insider Jung Choi Sells 3,000 Shares

Global Blood Therapeutics (NASDAQ:GBT) insider Jung Choi sold 3,000 shares of the business’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $48.25, for a total value of $144,750.00. Following the sale, the insider now directly owns 136,077 shares of the company’s stock, valued at approximately $6,565,715.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jung Choi also recently made the following trade(s):

  • On Tuesday, April 17th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $45.50, for a total value of $136,500.00.
  • On Friday, March 16th, Jung Choi sold 3,000 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $54.15, for a total value of $162,450.00.

Shares of Global Blood Therapeutics opened at $45.65 on Tuesday, according to Marketbeat. Global Blood Therapeutics has a 1-year low of $24.02 and a 1-year high of $68.05.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Monday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. During the same period in the previous year, the company posted ($0.60) earnings per share. analysts anticipate that Global Blood Therapeutics will post -3.68 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of GBT. Schwab Charles Investment Management Inc. boosted its holdings in Global Blood Therapeutics by 14.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 176,444 shares of the company’s stock valued at $6,944,000 after purchasing an additional 22,325 shares during the last quarter. GW&K Investment Management LLC raised its stake in Global Blood Therapeutics by 41.2% during the fourth quarter. GW&K Investment Management LLC now owns 145,717 shares of the company’s stock valued at $5,734,000 after buying an additional 42,519 shares in the last quarter. Fiduciary Trust Co. raised its stake in Global Blood Therapeutics by 17.1% during the fourth quarter. Fiduciary Trust Co. now owns 27,604 shares of the company’s stock valued at $1,086,000 after buying an additional 4,024 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in Global Blood Therapeutics during the fourth quarter valued at approximately $713,000. Finally, Taylor Wealth Management Partners raised its stake in Global Blood Therapeutics by 2.7% during the fourth quarter. Taylor Wealth Management Partners now owns 48,865 shares of the company’s stock valued at $1,923,000 after buying an additional 1,300 shares in the last quarter. 95.43% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the company. William Blair assumed coverage on Global Blood Therapeutics in a research report on Tuesday, January 23rd. They set an “outperform” rating and a $80.00 price target for the company. Zacks Investment Research raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. SunTrust Banks set a $80.00 target price on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 1st. ValuEngine raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub downgraded Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 4th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $69.85.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply